Aurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health Canada for its cancer drug Bevqolva. This approval marks a crucial step for the bevacizumab biosimilar. Bevqolva is used to treat various cancers. Health Canada's nod confirms its safety and efficacy. This opens new avenues for cancer treatment in Canada.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4Zb1YWw
via IFTTT
-
Lilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales ...
-
Acquista ********, Ossicodone, Ketamina, Ozempic (WhatsApp: +31616337954) I nostri prodotti hanno una purezza del 98-99%. E-mail di cont...
-
The Indian Pharmaceutical Alliance lauds the upcoming GST reforms, effective Monday, as a transformative step towards affordable healthcare....
Search This Blog
Powered by Blogger.
Recent Posts
Unordered List
Theme Support
-
Text Widget
Design by FlexiThemes | Blogger Theme by Lasantha - PremiumBloggerTemplates.com | Best Gadgets | Distributed By Gooyaabi Templates
0 comments:
Post a Comment